Cargando…

The role of PARP inhibitor combination therapy in ovarian cancer

The use of PARP inhibitors (PARPi) has transformed the care of advanced high-grade serous/endometrioid ovarian cancer. PARPi are now available to patients in both the first-line and recurrent platinum-sensitive disease settings; therefore, most patients will receive PARPi at some point in their trea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hockings, Helen, Miller, Rowan E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196552/ https://www.ncbi.nlm.nih.gov/pubmed/37215065 http://dx.doi.org/10.1177/17588359231173183

Ejemplares similares

PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies
por: Miller, Rowan E, et al.
Publicado: (2022)

Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP Inhibitors
por: Miller, Rowan E, et al.
Publicado: (2022)

Integration of PARP-inhibitors in ovarian cancer therapy
por: Pietragalla, Antonella, et al.
Publicado: (2020)

The Emerging Role of PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer
por: Gien, Lilian T., et al.
Publicado: (2010)

Perspectives on PARP Inhibitor Combinations for Ovarian Cancer
por: Bonadio, Renata Colombo, et al.
Publicado: (2021)

PARP Inhibitors in Breast and Ovarian Cancer
por: Wang, Samuel S. Y., et al.
Publicado: (2023)

An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer
por: Xu, Jing, et al.
Publicado: (2022)

PARP Inhibitors in Ovarian Cancer: The Route to “Ithaca”
por: Boussios, Stergios, et al.
Publicado: (2019)

The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy
por: Maiorano, Brigida Anna, et al.
Publicado: (2022)

PARP inhibitors in ovarian cancer
por: Cibula, David, et al.
Publicado: (2015)

PARP Inhibitors in Ovarian Cancer: A Review
por: O’Malley, David M., et al.
Publicado: (2023)

Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
por: Kim, Hyoung, et al.
Publicado: (2020)

New treatment option for ovarian cancer: PARP inhibitors
por: Meehan, Robert S., et al.
Publicado: (2016)

Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer
por: McMullen, Michelle, et al.
Publicado: (2020)

Combined treatment of disulfiram with PARP inhibitors suppresses ovarian cancer
por: Tang, Bin, et al.
Publicado: (2023)

PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms
por: Jiang, Xuan, et al.
Publicado: (2019)

Combining PARP and CDK4/6 inhibitors in MYC driven ovarian cancer
por: Konecny, Gottfried E.
Publicado: (2019)

Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy
por: Chen, Zheling, et al.
Publicado: (2021)

Immunomodulatory Roles of PARP-1 and PARP-2: Impact on PARP-Centered Cancer Therapies
por: Yélamos, José, et al.
Publicado: (2020)

Adaptive therapy for ovarian cancer: An integrated approach to PARP inhibitor scheduling
por: Strobl, Maximilian, et al.
Publicado: (2023)

PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?
por: Franzese, Elisena, et al.
Publicado: (2020)

Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancer
por: Veneziani, Ana C., et al.
Publicado: (2023)

Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer
por: Colombo, Ilaria, et al.
Publicado: (2018)

Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer
por: Revythis, Antonios, et al.
Publicado: (2022)

PARP inhibitors: its role in treatment of cancer
por: Chen, Alice
Publicado: (2011)

Advances in the use of PARP inhibitor therapy for breast cancer
por: McCann, Kelly E, et al.
Publicado: (2018)

Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors
por: Nero, Camilla, et al.
Publicado: (2021)

PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies
por: Lee, Elizabeth K., et al.
Publicado: (2020)

Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review
por: Boussios, Stergios, et al.
Publicado: (2019)

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
por: Morgan, Robert D., et al.
Publicado: (2018)

PARP inhibitor combinations in prostate cancer
por: Pezaro, Carmel
Publicado: (2020)

Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer
por: Jiang, Xuan, et al.
Publicado: (2019)

Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?
por: Klotz, Daniel Martin, et al.
Publicado: (2020)

BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer
por: Lui, Goldie Y.L., et al.
Publicado: (2020)

Quantitative Analysis of the Efficacy of PARP Inhibitors as Maintenance Therapy in Recurrent Ovarian Cancer
por: Gao, Lili, et al.
Publicado: (2021)

PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?
por: Barcellini, Amelia, et al.
Publicado: (2021)

Role of Akt Activation in PARP Inhibitor Resistance in Cancer
por: Gallyas, Ferenc, et al.
Publicado: (2020)

The role of PARP inhibitors in BRCA mutated pancreatic cancer
por: Chi, Jeffrey, et al.
Publicado: (2021)

Efficacy and Safety of PARP Inhibitor Combination Therapy in Recurrent Ovarian Cancer: A Systematic Review and Meta-Analysis
por: Ren, Ning, et al.
Publicado: (2021)

Role of Biomarkers in the Development of PARP Inhibitors
por: Ganguly, Bratati, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_rl72j49alcn5k85bobic88fdaj